CI

At a glance

ClinicalIndex Comparison Record
N/AUnknown· 50 target
Drug / intervention
in vitro NGS-panelother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03546452
NCT03546452N/AUnknown
CompareCT.gov

A Prospective Study to Evaluate the Results of Different NGS- Panels in Mutation Detection and Tumor Mutation Burden(TMB) Calculation by Using Malignant Hydrothorax From NSCLC

Shanghai Chest Hospital·observational·Posted Jun 6, 2018·Updated Jun 7, 2018

In Brief

An observational study evaluating in vitro NGS-panel for Malignant Hydrothorax and NSCLC. Targeting 50 participants across 1 site.

Detailed Summary

A prospective study to evaluate consistency of different NGS-panel. Cell free DNA is purified from each malignant hydrothorax from NSCLC .Different NGS-panels are applied to perform in vitro diagnosis to detect Single Nucleotide Variants(SNV) and to calculate TMB value in these DNA samples.Consistency of enrolled NGS-panels are then evaluated by statistical analysis.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Hydrothorax, NSCLC
CountriesChina
CollaboratorsSinotech Genomics Co., Ltd, Amoy Diagnostics, Guangzhou Burning Rock Medical Examination Institute Co., Ltd., Geneplus-Beijing Co. Ltd., Berry Genomics Co., Ltd.

Timeline

N/AUnknownOverdue
20192020202120222023202420252026
First PostedJun 6, 2018
Enrollment StartMay 18, 2018
Primary CompletionSep 30, 2018
Study CompletionMay 1, 2019
TodayJul 1, 2026
Enrollment to primary: 4 monthsPosted 8.1 years ago

Interventions

in vitro NGS-panelother

cell free DNA ,which was purified from hydrothorax, is used to be tested by NGS-panel